These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 14596699)

  • 1. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of pemetrexed in gastrointestinal cancer.
    Meriggi F; Di Biasi B; Caliolo C; Zaniboni A
    Chemotherapy; 2008; 54(1):1-8. PubMed ID: 18063861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pemetrexed: from preclinic to clinic].
    Lansiaux A; Lokiec F
    Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed: its promise in treating non-small-cell lung cancer.
    Manegold C
    Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):43-8. PubMed ID: 15339059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V; Patel JD; Argiris A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):511-22. PubMed ID: 15270656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of a promising new agent--pemetrexed disodium.
    Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
    Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
    Adjei AA
    Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
    Bunn PA
    Semin Oncol; 2002 Jun; 29(3 Suppl 9):17-22. PubMed ID: 12094334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed safety and dosing strategy.
    Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
    Calvert H
    Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pemetrexed/gemcitabine combination in pancreatic cancer.
    Kindler HL
    Cancer; 2002 Aug; 95(4 Suppl):928-32. PubMed ID: 12209673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.